论文部分内容阅读
对我国首次研究成功的伤寒Vi多糖菌酋进行了人体接种安全性、反应性、血清学效果和流行病学效果观察，各期观察达21万余人，结果证实伤寒Vi多糖茵茵安全世良好，反应轻微。血清学效果显示，30μg一次免疫，Vi抗体4倍增长可达91．6％。两次流行病学效果考核，按血培养伤寒杆菌阳性病例统计，保护率可达70％左右，茵茵的效果指数为3．29～3．49。该菌苗性质稳定，初免只需注射一针，替代现行菌体菌苗推广应用是完全可行的。
Safety, reactivity, serological and epidemiological effects were observed in the first successful research on typhoid Vi polysaccharide in our country. The number of observations was more than 21,000 in each period, and the results showed that the safety of typhoid Vi polysaccharide was safe , Reaction is slight. Serological results showed that 30μg of primary immunization, Vi antibody 4-fold increase of up to 91.6%. Two epidemiological assessment, according to the blood culture of typhoid bacilli positive cases statistics, the protection rate of up to 70%, the effect index of Yan is 3.29 ~ 3.49. The bacterin is stable in nature, only need to inject a needle in the first immunization, and it is totally feasible to popularize and apply the bacterium vaccine instead of the current bacterium.